Key clinical point: Addition of prophylactic ciprofloxacin and omission of maintenance prednisolone are associated with a lower risk of developing febrile neutropenia (FN) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving docetaxel plus androgen deprivation therapy (ADT).
Major finding: Cohort A had a significantly higher incidence of FN than cohort B (14.8% vs. 2.5%; P = .006).
Study details: The data come from 159 patients with mHSPC who commenced docetaxel chemotherapy. Cohort A (n = 81) received docetaxel+ADT along with prednisolone, whereas cohort B (n = 78) received docetaxel+ADT without prednisolone and with prophylactic ciprofloxacin.
Disclosures: No source of funding was identified. Kenrick Ng and Mark Linch reported relationships with pharmaceutical companies. The other authors declared no conflicts of interest.
Pemberton L et al. Prostate Cancer Prostatic Dis. 2020 Jul 24. doi: 10.1038/s41391-020-0261-z.